Hyperkalemia management in heart failure and chronic kidney disease: a Spanish cost-effectiveness analysis of patiromer informed by the integrated DIAMOND trial and real-world evidence

The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis

Best-Practice Biomarker Testing of Oesophago-Gastric Cancer in the UK: Expert Consensus Recommendations Developed Using a Modified Delphi

The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?

Cost offset of dapagliflozin in the US Medicare population with cardio-kidney metabolic syndrome

Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial 

Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis

Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence

Budget impact analysis of expanding gliflozin coverage in the CKD population: a French perspective